Introduction. While occurring in 30–40% pregnant women, Candida vulvovaginitis is diagnosed in almost 45–50% patients before delivery. At the same time, unfavourable course and outcome of pregnancy in relation to the given pathology is, first of all, associated with high rate of gestational complications, complications in delivery and in postpartum period, as well as the risk of ante- and intranatal infecting of a fetus.
Aim of the research. Evaluation of the clinical effectiveness of using a probiotic Fermalak for treatment of recurrent Candida vulvovaginitis in pregnant women.
Materials and methods. 50 pregnant women with recurrent Candida vulvovaginitis have been examined and treated. The patients of the first group (the basic one) (n=25) received traditional antimycotic therapy combined with the probiotic. The patients of the second group (the control one) (n=25) received only intravaginal suppository of an antimycotic sertaconazole nitrate once.
Results of the research and their discussion. The conducted research allowed us to determine the clinical effectiveness (100%), mycotic recovery (68%) and stubbornly low degree of semination (32%) in pregnant women with recurrent Candida vulvovaginitis. A significant increase of serum IgA level ((2.35±0.09) g/l) in the group of patients, who received antimycotic therapy combined with the probiotic Fermalak.
Conclusions. Clinical effectiveness, immunobiological effect and a broad spectrum of activity of the drug allow us to consider the probiotic Fermalak as a highly effective and safe remedy in complex treatment of recurrent Candida vulvovaginitis in pregnant women.